$1,100,000 for Beat Childhood Cancer Research!
On December 24, 2014 the Grand Rapids community surpassed the Million Dollar Challenge by raising $1,100,000 for NMTRC research! This donation was then matched by a generous Beat NB donor[...]
Endowment Gift Establishes Haworth Family Pediatric Oncology Innovative Therapeutics Clinic at Helen Devos Children’s Hospital
Children fighting cancer have new hope thanks to an endowment gift from Dick and Ethie Haworth to the Helen DeVos Children’s Hospital Foundation. Their major gift establishes the Haworth Family[...]
Research: Beat Childhood Cancer
The Beat Childhood Cancer Research Consortium is a group of 54+ universities and children's hospitals
Big news!! The Beat Childhood Cancer (BCC) Research Consortium at Penn State University has partnered with the National Cancer Institute (NCI) Clinical Proteomic Tumor Analysis Consortium (#CPTAC) 🤝. Both consortiums aim to better understand each child’s tumor and improve care through advanced proteomic + genomic testing. CPTAC and BCC will work closely with Penn State’s Precision Medicine Program and Molecular Tumor Board team to assess whether proteomic findings could refine, confirm, or modify therapy recommendations for individual patients. This collaborative review process is designed to evaluate the real-world clinical utility of proteomics in treatment decision-making, particularly in complex or ambiguous cases.
dctd.cancer.gov/about/news-events/news/2025-news/collaboration?cid=eb_govdel
The Beat Childhood Cancer Research Consortium is thrilled to welcome GRAACC Hospital in São Paulo, Brazil!!
GRAACC is a renowned leader in caring for children with complex cancers, and this partnership expands access to innovative clinical trials for families across Latin America. Together, we’re accelerating discovery, advancing equitable care, and bringing hope to children everywhere.
Our group now spans over 55 hospitals across 3 continents. This is something we have been dreaming about for a while now and it is now a reality. Our first study, BCC018, to open in Brazil is submitted to the regulatory authorities and is pending approval to open enrollment.
Read more in our press release: pennstatehealthnews.org/2026/02/penn-states-beat-childhood-cancer-research-consortium-welcomes-gr...
#PediatricCancer #GlobalResearch #BeatChildhoodCancer #GRAACC #PennState #ClinicalTrials
Penn State’s Beat Childhood Cancer Research Consortium welcomes GRAACC Hospital in São Paulo
pennstatehealthnews.org
Penn State College of Medicine and the Beat Childhood Cancer (BCC) Research Consortium are proud to announce the addition of GRAACC Hospital in São Paulo, one of Brazil’s leading pediatric oncology...
Every day, they remind us why we do this work. Their laughter, their courage, their imaginations, their futures...this is what drives the Beat Childhood Cancer Research Consortium.
We fight for more moments, more milestones, and more tomorrows for every child and family facing a childhood cancer diagnosis.
#beatchildhoodcancer #ourwhy #pediatriccancerresearch #clinicaltrialssavelives #PennStateHealth
A new study demonstrating the potential of GB13 as an effective treatment strategy for diffuse intrinsic pontine glioma (DIPG) has been published in Nature Communications Biology.
In this study, GB13 was evaluated across multiple animal models of DIPG. When administered directly into tumors via convection-enhanced delivery (CED), GB13 significantly reduced tumor volume and improved overall survival. Importantly, the findings support a clinical strategy to enhance standard-of-care radiation therapy. Animals treated with GB13 prior to radiation exhibited smaller tumors and longer survival compared with radiation or GB13 treatment alone. Notably, CURATIVE outcomes were observed in a human-derived DIPG model.
We are excited to build upon this data to develop our BCC024 Clinical Trial focused on targeting GB13 in pediatric DIPG patients! We are working with both the FDA and the company, Targepeutics, to make this treatment a reality for our patients.
See the full article here: www.nature.com/articles/s42003-025-09155-9
If you missed it, check out the Little Warriors Foundation Webinar with Dr. David Loeb, the Study Chair of our upcoming BCC023 trial: A Phase II Open Label Basket Trial Study Using Eflornithine (DFMO) for Ewing Sarcoma and Osteosarcoma. There are 5 separate cohorts covered under this master protocol to use DFMO in combination or in a maintenance setting.
We expect this trial to be available to sites across our BCC Consortium very soon! Check out more information here:https://clinicaltrials.gov/study/NCT07321912
www.littlewarrior.org/blog/dr-david-loeb-a-phase-ii-open-label-basket-trial-study-using-eflornith...
www.littlewarrior.org
Dr. David Loeb (Children's Hospital at Montefiore) makes a repeat guest appearance to present and discuss an upcoming Phase II Clinical Trial centered around DFMO for Ewing sarcoma and Osteosarcoma.
NEW PUBLICATION ALERT: On December 17, 2025, In vitro and in vivo efficacy of romidepsin alone and in addition to standard of care for treatment of Ewing sarcoma was published in Cancers.
HDAC inhibitors were tested on Ewing sarcoma cells in the lab and a drug called romidepsin was found to be most effective. In animal studies, the combination of romidepsin and ifosfamide/etoposide (IE) led to a significant decrease in tumor volume compared to that of IE alone. Thank you to our collaborators at Atrium Health in Charlotte, NC and the patients who dedicated both their samples and clinical data to make this work possible!
Read the full article: pubmed.ncbi.nlm.nih.gov/41463266/